Exenatide
AGREE
AstraZeneca · Phase 2/3 · Status n/r · Enrollment 28
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Exenatide | n/r | n/r | n/r | n/r |
| Placebo | n/r | n/r | n/r | n/r |
Not shown
- Exenatide: endpoint not reported
- Placebo: endpoint not reported